http://www.nanotech-now.com/news.cgi?story_id=26982 Google Search Web Nanotech Now Nanoengineering Research The Nanotech Revolution Is Upon Us. Free Investor Research Report. www.WealthDaily.com/NanotechRpt Journal of Nanoengineering and Nanosystems journals.pepublishing.com/jnn Home > Press > Cheaper Drugs Now Closer to Realization with New DropArray Technology www.nanotech-now.com The latest news from around the world, FREE Full Name Email Address Subscribe Abstract: Ads by Google IBN's First Spin-off Company, Curiox Biosystems, to Bring DropArray to Market Cheaper Drugs Now Closer to Realization with New DropArray Technology Singapore | Posted on December 17th, 2007 Our NanoNews Digest A standard laboratory tool for measuring pharmacological activity of biological substances and performing other related tests may soon be replaced by a new Sponsors miniaturized bioassay that will be faster, cheaper and more efficient for scientists to use, with new technology developed by Singapore's Institute of Bioengineering and Nanotechnology (IBN). The new assay, named DropArray, slashes the time needed to run certain lab tests by over 60 per cent and reduces consumable costs by nearly 90 per cent, while maintaining the same level of flexibility and convenience as conventional platforms. According to IBN Team Leader Dr Namyong Kim, "Our technology has the potential to accelerate life science, drug discovery and clinical research. Using our technology, companies can benefit from huge savings in time and money spent on research and development and this would have a direct impact on the cost of medication and new drugs for the consumer." IBN's DropArray represents a unique integration of surface chemistry and microfluidics designed to reduce the amount of material and reagent required by up to 1,000 times, while simultaneously cutting the reaction time by up to 10 folds, making it faster and cheaper than standard bioassays. Each DropArray chip comprises a small (1 inch by 3 inch) flat rectangular patterned glass slide, with hundreds or thousands of hydrophilic glass "wells" surrounded by a hydrophobic coating. These chips can be used for common laboratory processes such as the heterogeneous bioassay, which is typically used by scientists in diagnostic tests to determine how a blood sample interacts with various other substances. The "wells" act as small test tubes in which the reagents are added, mixed and incubated, and a benchtop station automatically completes the rinsing process in heterogeneous bioassay. Nano Market Nano Sensors Nano Industry Nano News Nanotech Premium Products Only the news you want to read! Learn More University Technology Transfer & Patents Learn More Full-service, expert consulting Learn More Highly tailored technology monitoring service Learn More IBN's DropArray is able to miniaturize bioassays from 50-100 microliters down to 100 nanoliters, making it possible for researchers to conduct various cell-based tests including cancer stem cell immunoassays that had previously been extremely challenging with conventional technology. Furthermore, the reduction in the volume of samples and reagents required provides similar advantages for protein-based assays such as ELISA with limited human and animal serum such as Human Leptin and Endostatin assays. "This DropArray was realized through the efforts of an interdisciplinary team of researchers, which is typical of the project-oriented research at IBN," said Prof Jackie Y. Ying, Executive Director of IBN, one of the 14 research institutes of Singapore's Agency for Science, Technology and Research (A*STAR). Prof. Ying was one of the youngest professors at the Massachusetts Institute of Technology, and has received many awards for her research in nanotechnology. She was elected to the German Academy of Natural Scientists, Leopoldina, in April 2005 as the youngest member of the Academy. "IBN was established less than 5 years ago with the mission to conduct exciting scientific research with significant commercial impact. Since then, we have filed more than 420 patents, and we are delighted that our entrepreneurial research team of one chemist, one biologist, one biomedical engineer, one mechanical engineer and one chemical engineer has taken less than three years to develop a novel technology platform that would contribute significantly to reducing the cost of drug development and medication. Curiox Biosystems, the company we set up to market this technology, is IBN's first spinoff." Subscribe to the Forbes/Wolfe Nanotech Report & Get 2 Free Reports Nanotechnology Now Featured Books http://www.nanotech-now.com/news.cgi?story_id=26982 Nanostart AG, the German-based world's leading nanotechnology investment company, has invested in Curiox Biosystems, which will further develop and commercialize the DropArray technology. Curiox will be headed by 2 IBN researchers, Dr. Kim Nam Yong, a Korean and Singapore permanent resident who received his Ph.D. in Chemistry from the Massachusetts Institute of Technology, and Dr. Leck Kwong Joo, a Singaporean who received his Ph.D. in Medical Sciences from the Australian National University. For Nanostart AG, the investment in Curiox marks its first in Asia, and is of strategic importance. Nanostart is investing in Curiox as the lead investor and is thus assuming an active role with its investment managers in the ongoing development of the company, jointly with Exploit Technologies, the commercialization arm of A*STAR. "Our new investment holding, Curiox, is our first step into the highly promising Asian market," explained Marco Beckmann, CEO of Nanostart AG. "Singapore has established an outstanding position for itself in Asia in nanotechnology. Through our investment in Curiox, we aim to directly participate in the dynamic growth of this region and to live up to our claim of global leadership. Further investments in Asia will follow." "We are delighted to learn that Nanostart is planning further activities including a local office in Singapore. It would bring along a significant international network of business contacts, and help other local enterprises in creating high value added jobs based on home-grown, cutting-edge technologies," said Prof. Ying. She will hold a seat on the company's board of directors along with a representative from Nanostart AG. Nanotechnology Now visitors receive a 10% discount on the Nanopolis educational series Exploring Nanotechnology, Exploring Matter with Synchrotron Light and Exploring Matter with Neutrons when using this link. The U.S. represents Curiox's largest potential market with more than 12,000 suitable academic and government labs, which spent $14.3 billion on lab instruments, consumables and reagents in 2005, and more than 14,000 industrial pharma and biotech labs, which spent $37.4 billion in 2005. #### About IBN The Institute of Bioengineering and Nanotechnology (IBN) is a member of the Agency for Science, Technology and Research (A*STAR). Established in March 2003, IBN is headed by its Executive Director, Professor Jackie Y. Ying. The Institute’s mission is to establish a broad knowledge base and conduct innovative research at the interface of bioengineering and nanotechnology. Positioned at the frontiers of engineering, IBN is focused on creating knowledge and cultivating talent to develop technology platforms in the following six areas: Delivery of Drugs, Proteins and Genes Cell and Tissue Engineering Artificial Organs and Implants Pharmaceuticals Synthesis and Nanobiotechnology Medical and Biological Devices Bioimaging and Biosensing For more information, please click here Subscribe to the Forbes/Wolfe Nanotech Report & Get 2 Free Reports Nanotechnology Global Technology News & Analysis for the world's decision-makers www.ft.com Sub-50nm Lithography Lithography for nanotechnology and semiconductor applications Contacts: Nidyah Sani Phone: +65 6824 7005 Mobile: 65 9762 9720 nidyah@ibn.a-star.edu.sg www.molecularimprints.com Laura Lau (IBN) DID: 65 6824 7040 Mobile: 65 9695 7521 Email: sslau@ibn.a-star.edu.sg Copyright © IBN If you have a comment, please Contact us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content. Nanotech Now Nanoengineering Research The Nanotech Revolution Is Upon Us. Free Investor Research Report. www.WealthDaily.com/NanotechRpt Journal of Nanoengineering and Nanosystems journals.pepublishing.com/jnn Related News Press Nanotechnology Research Cutting Edge Infrastructure, Great Funding Pursue Research At NTU! NTU-Singapore.com Nanotechnology Stock News Investment e-Letter Long & Short D Brookstein of Nanotechnology.com www.Nanotechnology.com Nanomedicine Platypus Technologies announcing the addition of the Oris™ Cell Migration Assay – Collagen Coated kit to its product line of cellular assays December 17th, 2007 Barnes&Noble.com http://www.nanotech-now.com/news.cgi?story_id=26982 MIT works toward engineered blood vessels December 17th, 2007 'Nanomedicine is at the frontline of new drug delivery' December 15th, 2007 CNSI and NanoPacific Holdings, Inc. Announce a Partnership to Develop and Commercialize Technologies Invented at the CNSI at UCLA December 14th, 2007 Announcements Technion releases first ever nano-Bible December 17th, 2007 Piezo Beam Steering Mirror Platforms Provide Larger Angles, High Bandwidth & Stability December 17th, 2007 New property found in ancient mineral lodestone: Latest nanofabrication methods yield new clues about well-studied mineral December 17th, 2007 Nanotechnology & the Media: The Inside Story December 17th, 2007 Tools Piezo Beam Steering Mirror Platforms Provide Larger Angles, High Bandwidth & Stability December 17th, 2007 Quantum nanotoxicity December 17th, 2007 IBM Commemorates 60th Anniversary of the Transistor and Decades of Innovations December 15th, 2007 From Children's Bladders To The iPhone December 14th, 2007 blog~nano Building Gods Quantum leap Inapplicable Intuitions © Copyright 1999-2007 7thWave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE